Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors

  • Anna Kezerashvili
  • Himad Khattak
  • Aron Barsky
  • Reza Nazari
  • John D. Fisher


During treatment with azithromycin, a 55 year-old woman developed a newly prolonged QT interval and torsade de pointes in the absence of known risk factors. Female gender and acute renal failure may be considerations in patients treated with azithromycin.


Azithromycin QT interval Torsade de Pointes LQTS 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Haverkamp, W., Breithardt, G. R., Camm, A. J., Janse, M. J., Rosen, M. R., Antzelevitch, C., et al. (2000). The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Cardiovascular Research, 47, 219–233.PubMedCrossRefGoogle Scholar
  2. 2.
    Moss, A. J, Schwartz, P. J., Crampton, R. S., Tzivoni, D., Locati, E. H., MacCluer, J., et al. (1991). The long QT syndrome. Prospective longitudinal study of 328 families. Circulation, 84, 1136–1144.PubMedGoogle Scholar
  3. 3.
    Brandriss, M. W., Richardson, W. S., & Barold, S. S. (1994). Erythromycin-induced QT prolongation and polymorphic tachycardia (torsades de pointes): Case report and review. Clinical Infectious Diseases, 18, 995–998.PubMedGoogle Scholar
  4. 4.
    Lee, K. L., Jim, M. H., Tang, S. C., & Tai, Y. T. (1998). QT prolongation and Torsades de Pointes associated with clarithromycin. American Journal of Medicine, 104, 395–396.PubMedCrossRefGoogle Scholar
  5. 5.
    Rubinstein, E. (2001). Comparative safety of the different macrolides. International Journal of Antimicrobial Agents, 18(Suppl 1), 71–76.CrossRefGoogle Scholar
  6. 6.
    Samarendra, P., Kumari, S., Evans, S. J., Sacchi, T. J., & Navaro, V. (2001). QT Prolongation Associated with Azithromycin/Amiodarone combination. PACE, 24, 1572–1574.PubMedGoogle Scholar
  7. 7.
    Arellano-Rodrigo, E., Garcia, A., Mont, L., & Roque, M. (2001). Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome. Medical Clinic (Barc), 117, 118–119.Google Scholar
  8. 8.
    Matsunaga, N., Oki, Y., & Prigollini, A. (2003). A case of QT interval prolongation precipitated by azithromycin. New Zealand Medical Journal, 1, 1185–1186.Google Scholar
  9. 9.
    Strle, F., & Maraspin, V. (2002). Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr, 114, 396–399.PubMedGoogle Scholar
  10. 10.
    Kim, M. H., Berkowitz, C., & Trohman, R. G. (2005). Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. PACE, 28, 1221–1222.PubMedGoogle Scholar
  11. 11.
    Milberg, P., Eckardt, L., Bruns, H. J., Biertz, J., Ramtin, S., Reinsch, N., et al. (2002). Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. Journal of Pharmacology and Experimental Therapeutics, 303, 218–225.PubMedCrossRefGoogle Scholar
  12. 12.
    Eckardt, L., Breithardt, G., & Haverkamp, W. (2002). Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: Low torsadogenic potential despite QT-prolongation. Journal of Pharmacology and Experimental Therapeutics, 300, 64–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Höffler, D., Paeske, B., & Koeppe, P. (1995). Pharmacokinetics of azithromycin in normal and impaired renal function. Infection, 23, 356–361.PubMedCrossRefGoogle Scholar
  14. 14.
    Bonnar, C. E., Davie, A. P., Caruana, L., Fenn, L., Ogston, S. A., McMurray, J. J. V., et al. (1999). QT dispersion in patients with chronic heart failure: β Blockers are associated with a reduction in QT dispersion. Heart, 81, 297–302.PubMedGoogle Scholar
  15. 15.
    Ex Card Research
  16. 16.
    Drici, M. D., Knollmann, B. C., Wang, W. X., & Woosley, R. L. (1998). Cardiac actions of erythromycin: Influence of female sex. Journal of the American Medical Association, 280, 1774–1776.PubMedCrossRefGoogle Scholar
  17. 17.
    Makkar, R. R., Fromm, B. S., Steinman, R. T., Meissner, M. D., & Lehmann, M. H. (1993). Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Journal of the American Medical Association, 270, 2590–2597.PubMedCrossRefGoogle Scholar
  18. 18.
    Lorincz, I., Matyus, J., Zilahi, Z., Kun, C., Karanyi, Z., & Kakuk, G. (1999). QT dispersion in patients with end-stage renal failure and during hemodialysis. Journal of the American Medical Association, 10, 1297–1302.Google Scholar
  19. 19.
    Ozdemir, D., Mese, T., Agin, H., Calkavur, S., & Bak, M. (2005). Impact of haemodialysis on ATc dispersion in children. Nephrology, 10, 119–122.PubMedCrossRefGoogle Scholar
  20. 20.
    Sarlagadda, S., & Perazella, M. (2006). Acute renal failure in the hospital: Diagnosis and management. Hospital Physician, 51–58.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Anna Kezerashvili
    • 1
  • Himad Khattak
    • 1
  • Aron Barsky
    • 1
  • Reza Nazari
    • 1
  • John D. Fisher
    • 1
  1. 1.Department of Medicine, Cardiology Division, Arrhythmia ServiceMontefiore Medical Center/Cardiology—N2, Albert Einstein College of MedicineBronxUSA

Personalised recommendations